USFDAMay 29, 2026, 10:02 AM
Replimune to Resubmit RP1 BLA for Advanced Melanoma After FDA Talks
AI Summary
Replimune Group, Inc. announced its plan to resubmit the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma. This decision follows productive discussions with the U.S. Food and Drug Administration (FDA), which has aligned on a path forward for reconsideration. The FDA has committed to treating the resubmission as an urgent matter and prioritizing its review, acknowledging the significant unmet need for patients with advanced melanoma. The BLA is supported by data from the IGNYTE clinical trial.
Key Highlights
- Replimune will resubmit its Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec).
- The BLA is for RP1 in combination with nivolumab for the treatment of advanced melanoma.
- The resubmission follows collaborative communications and alignment with the U.S. Food and Drug Administration (FDA).
- The FDA will treat the BLA resubmission as an urgent matter and prioritize its review.
- The BLA is supported by data from the IGNYTE clinical trial.
- Approximately 8,500 Americans with advanced melanoma die each year.
- Standard anti-PD-1 based therapy fails approximately half of all patients.
Price Impact
More from REPL